Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523181 · ClinicalTrials.gov registry record · Phase 2
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
A Phase 2 study of COVID-19, sponsored by Golden Biotechnology Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 15
- Study locations
NCT04523181 is a Phase 2 study of COVID-19 that has completed, run by Golden Biotechnology Corporation. The registered enrollment target is 124 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT04523181, a Phase 2 study of COVID-19, has completed, sponsored by Golden Biotechnology Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 15
- Study locations
Study Summary
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Antroquinonol
Study Locations (15)
Other
- Unidad de Investigacion, Hospital Nacional IV Alberto Sabogal Sologuren-Essalud, Red Assitencial Sabogal - Callao
- Hospital de Chancay - Chancay
- Asociación Civil Selva Amazónica - Iquitos
- Hospital III Daniel Alcides Carrion - EsSalud - Tacna
Buenos Aires F.D.
- Centro Gallego - Buenos Aires
- Clinica de los Virreyes - Buenos Aires
Indiana
- Franciscan Health Michigan City - Michigan City
Kansas
- Ascension.Via Christi Research - Wichita
Maryland
- Adventist Healthcare Shady Grove Medical Center - Rockville
New Jersey
- South Jersey Infectious Disease - Somers Point
North Carolina
- Duke University Southeastern Health - Lumberton
Ciudad de Cordoba
- Sanatorio Privado Mayo SA - Córdoba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04523181
The ClinicalTrials.gov registry entry for NCT04523181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Golden Biotechnology Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04523181 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Other, Buenos Aires F.D., Indiana.
Frequently Asked Questions
What is clinical trial NCT04523181 about?
NCT04523181 is a clinical study titled "Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients". To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
What is the current status of trial NCT04523181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2020-10-15. Estimated completion is 2021-12-23.
What conditions does trial NCT04523181 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04523181?
The interventions under investigation include: Placebo (OTHER), Antroquinonol (DRUG).
Who is sponsoring clinical trial NCT04523181?
This trial is sponsored by Golden Biotechnology Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04523181 being conducted?
This trial has 15 study locations across Indiana, Kansas, Maryland, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.